top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Journal of Health and Medical Sciences

ISSN 2622-7258

Screen Shot 2018-08-12 at 1.24.09 AM.png
Screen Shot 2018-08-12 at 1.24.02 AM.png
Screen Shot 2018-08-12 at 1.23.57 AM.png
Screen Shot 2018-08-12 at 1.23.52 AM.png
open access

Published: 06 November 2020

Schizophrenia: Epidemiology, Causes, Neurobiology, Pathophysiology, and Treatment

Kevin Volkan

California State University Channel Islands (USA), Community Memorial Health System (USA)

journal of social and political sciences
pdf download

Download Full-Text Pdf



Pages: 487-521

Keywords: Schizophrenia, Autoimmunity, Brain Structure, Antipsychotic Medication, Neuromodulation, Psychotherapy


Schizophrenia is a severe mental illness that has devastating consequences for those who suffer from the disorder. The epidemiology of schizophrenia indicates that it occurs relatively often, in many different contexts, and in conjunction with other disorders, decreasing quality of life and causing premature death. There has been an enormous amount of research into the causes of schizophrenia and there is now have a much better understanding of the genetic, environmental, and psychological factors that contribute to the disease. While there are numerous ways to understand and conceptualize schizophrenia, a unified picture of the neurobiology, changes in brain structure, cognitive and social-cognitive impairments related to the disorder has yet to emerge. Convulsive therapies and psychosurgery were used unsuccessfully, indiscriminately and without scientific validation in the past to treat schizophrenia. Medical advances including advanced imaging technology have now provided the ability to perform specifically focused neuromodulation and psychosurgery in severe and treatment resistant cases of schizophrenia. While still at a preliminary stage, these approaches have the potential to yield effective treatments in the future. For the last 70 years antipsychotic medication has become the prevailing treatment for schizophrenia. However, many people suffering from the disorder have trouble with side-effects and adhering to a regimen of antipsychotic medication. Newer pharmacological agents are being developed and include not only novel antipsychotic drugs, but anti-inflammatory and immunomodulating agents as well. These new agents, used either alone or in combination, have the potential to improve outcomes for people suffering from schizophrenia. Nevertheless, conclusively better pharmacotherapies will likely not arise until there is better understanding of the pathophysiology underlying schizophrenia. After the development of antipsychotic medication, psychotherapeutic methods for treating schizophrenia fell out of favor, but there is currently some reversal of this trend. The use of newer psychotherapies and modified forms of older therapeutic treatments are not only targeting the symptoms of schizophrenia but are also now focusing on recovery from the disorder. These newer approaches as well as efforts at preventing schizophrenia show promise in reducing the suffering caused by this disease.


  1. Adams, D. D., Knight, J. G., & Ebringer, A. (2012). The autoimmune model of schizophrenia. ISRN Psychiatry, 2012, 758072.

  2. Agarwal, V., Abhijnhan, A., & Raviraj, P. (2007). Ayurvedic medicine for schizophrenia. The Cochrane Database of Systematic Reviews, 4, CD006867.

  3. Agbeli, M. O. (2020). Reducing antipsychotic medication use in long-term care settings (2020-04052-126; Issues 5-A). ProQuest Information & Learning.

  4. Akhtar, S., & Volkan, V. D. (2005). Mental zoo: Animals in the human mind and its pathology. International Universities Press.

  5. Albert, N., Randers, L., Allott, K., Jensen, H. D., Melau, M., Hjorthøj, C., & Nordentoft, M. (2019). Cognitive functioning following discontinuation of antipsychotic medication A naturalistic sub-group analysis from the OPUS II trial. Psychological Medicine, 49(7), 1138–1147.

  6. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5 (5 edition). American Psychiatric Publishing.

  7. Angyal, A. (1950). The psychodynamic process of illness and recovery in a case of catatonic schizophrenia. Psychiatry: Journal for the Study of Interpersonal Processes, 13, 149–165.

  8. Arnaiz, A., Zumárraga, M., Díez-Altuna, I., Uriarte, J. J., Moro, J., & Pérez-Ansorena, M. A. (2011). Oral health and the symptoms of schizophrenia. Psychiatry Research, 188(1), 24–28.

  9. Ashcroft, K., Kingdon, D. G., & Chadwick, P. (2012). Persecutory delusions and childhood emotional abuse in people with a diagnosis of schizophrenia. Psychosis: Psychological, Social and Integrative Approaches, 4(2), 168–171.

  10. Azrin, S. T., Goldstein, A. B., & Heinssen, R. K. (2015). Early intervention for psychosis: The Recovery After an Initial Schizophrenia Episode project. Psychiatric Annals, 45(11), 548–553.

  11. B, S., & Tk, C. (2014). Role of C-reactive protein in schizophrenia: An overview. Psychiatry Research, 216(2), 277–285.

  12. Barkan, T., Peled, A., Modai, I., Barak, P., Weizman, A., & Rehavi, M. (2006). Serotonin transporter characteristics in lymphocytes and platelets of male aggressive schizophrenia patients compared to non-aggressive schizophrenia patients. European Neuropsychopharmacology, 16(8), 572–579.

  13. Barrowclough, C., Haddock, G., Lobban, F., Jones, S., Siddle, R., Roberts, C., & Gregg, L. (2006). Group cognitive-behavioural therapy for schizophrenia. British Journal of Psychiatry, 189(6), 527–532.

  14. Baumeister, A. A., & Francis, J. L. (2002). Historical development of the dopamine hypothesis of schizophrenia. Journal of the History of the Neurosciences, 11(3), 265–277.

  15. Beraki, S., Aronsson, F., Karlsson, H., Ögren, S. O., & Kristensson, K. (2005). Influenza A virus infection causes alterations in expression of synaptic regulatory genes combined with changes in cognitive and emotional behaviors in mice. Molecular Psychiatry, 10(3), 299–308.

  16. Bhugra, D. (2000). Migration and schizophrenia. Acta Psychiatrica Scandinavica, 102, 68–73.

  17. Bonnigal-Katz, D. (2019). Psychosis Therapy Project: A psychoanalytic project in the community. British Journal of Psychotherapy, 35(4), 586–589.

  18. Boydell, J., Van Os, J., Lambri, M., Castle, D., Allardyce, J., McCreadie, R. G., & Murray, R. M. (2003). Incidence of schizophrenia in south-east London between 1965 and 1997. British Journal of Psychiatry, 182(1), 45–49.

  19. Brakoulias, V., Starcevic, V., Albert, U., Arumugham, S. S., Bailey, B. E., Belloch, A., Borda, T., Dell’Osso, L., Elias, J. A., Falkenstein, M. J., Ferrao, Y. A., Fontenelle, L. F., Jelinek, L., Kalogeraki, L., Kay, B., Laurito, L. D., Lochner, C., Maina, G., Marazziti, D., … Fineberg, N. A. (2019). Treatments used for obsessive-compulsive disorder-An international perspective. Human Psychopharmacology, 34(1), e2686.

  20. Brambilla, P., & Tansella, M. (2007). Can neuroimaging studies help us in understanding the biological causes of schizophrenia? International Review of Psychiatry, 19(4), 313–314.

  21. Braslow, J. T. (1999). History and evidence-based medicine: Lessons from the history of somatic treatments from the 1900s to the 1950s. Mental Health Services Research, 1(4), 231–240.

  22. Bray, I., Waraich, P., Jones, W., Slater, S., Goldner, E. M., & Somers, J. (2006). Increase in schizophrenia incidence rates: Findings in a Canadian cohort born 1975-1985. Social Psychiatry and Psychiatric Epidemiology, 41(8), 611–618.

  23. Bresnahan, M., Menezes, P., Varma, V., & Susser, E. (2003). Geographical variation in incidence, course and outcome of schizophrenia: A comparison of developing and developed countries. The Epidemiology of Schizophrenia., 18–33.

  24. Brown, A. S., & McGrath, J. J. (2011). The Prevention of Schizophrenia. Schizophrenia Bulletin, 37(2), 257–261.

  25. Brown, A. S., & Patterson, P. H. (2011). Maternal Infection and Schizophrenia: Implications for Prevention. Schizophrenia Bulletin, 37(2), 284–290.

  26. Brown, A. S., Schaefer, C. A., Quesenberry, C. P. Jr., Shen, L., & Susser, E. S. (2006). No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia? American Journal of Psychiatry, 163(12), 2178–2180.

  27. Brown, S., Inskip, H., & Barraclough, B. (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212–217.

  28. Buckley, L., & Pettit, T. (2007). Supportive therapy for schizophrenia. Schizophrenia Bulletin, 33(4), 859–860.

  29. Buka, S. L., Cannon, T. D., Torrey, E. F., & Yolken, R. H. (2008). Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biological Psychiatry, 63(8), 809–815.

  30. Burns, J. (2007). The Descent of Madness: Evolutionary Origins of Psychosis and the Social Brain (1 edition). Routledge.

  31. Butler, P. D., Susser, E. S., Brown, A. S., Kaufmann, C. A., & Gorman, J. M. (1994). Prenatal nutritional deprivation as a risk factor in schizophrenia: Preclinical evidence. Neuropsychopharmacology, 11(4), 227–235.

  32. Byrne, M., Agerbo, E., Bennedsen, B., Eaton, W. W., & Mortensen, P. B. (2007). Obstetric conditions and risk of first admission with schizophrenia: A Danish national register based study. Schizophrenia Research, 97(1), 51–59.

  33. Capasso, R. M., Lineberry, T. W., Bostwick, J. M., Decker, P. A., & St. Sauver, J. (2008). Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950-2005. Schizophrenia Research, 98(1), 287–294.

  34. Caruso, J. P., & Sheehan, J. P. (2017). Psychosurgery, ethics, and media: A history of Walter Freeman and the lobotomy. Neurosurgical Focus, <